Synonym
VRX-806; VRX 806; VRX806; AR-806; AR 806; AR806; RDEA-806; RDEA 806; RDEA806.
IUPAC/Chemical Name
4-(2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetamido)-3-chlorobenzoic acid
InChi Key
MPNGLQDRSJNLPL-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H18BrClN4O3S/c25-23-28-29-24(34-12-21(31)27-19-9-7-14(22(32)33)11-18(19)26)30(23)20-10-8-15(13-5-6-13)16-3-1-2-4-17(16)20/h1-4,7-11,13H,5-6,12H2,(H,27,31)(H,32,33)
SMILES Code
O=C(O)C1=CC=C(NC(CSC2=NN=C(Br)N2C3=C4C=CC=CC4=C(C5CC5)C=C3)=O)C(Cl)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
557.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Li W, Li X, De Clercq E, Zhan P, Liu X. Discovery of potent HIV-1
non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide
structural motif. Eur J Med Chem. 2015 Sep 18;102:167-79. doi:
10.1016/j.ejmech.2015.07.043. Epub 2015 Jul 26. Review. PubMed PMID: 26276432.
2: Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a
review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS
Soc. 2013 Sep 4;16:1-14. doi: 10.7448/IAS.16.1.18567. Review. PubMed PMID:
24008177; PubMed Central PMCID: PMC3764307.
3: Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K, Sheedy B, Hingorani
V, Raney A, Nguyen M, Nguyen T, Ong V, Yeh LT, Quart B. Phase 2a randomized
controlled trial of short-term activity, safety, and pharmacokinetics of a novel
nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive,
antiretroviral-naive subjects. Antimicrob Agents Chemother. 2010
Aug;54(8):3170-8. doi: 10.1128/AAC.00268-10. Epub 2010 May 24. PubMed PMID:
20498326; PubMed Central PMCID: PMC2916334.
